Business Segments Valerio Therapeutics Börse Stuttgart
Stocks
C4X
FR0010095596
Pharmaceuticals
|
Market Closed -
Other stock markets
|
Pre-market 01:39:29 | |||
| 0.0540 EUR | +58.82% |
|
0.7540 | +1,296.30% |
| 07-16 | Valerio Therapeutics, Abivax Enter R&D Collaboration for Inflammatory Disease Therapies | MT |
| 07-16 | Valerio Therapeutics, Abivax Sign R&D Deal for Inflammatory Diseases' Drug Candidates | MT |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Biological Products | ||||||||||
Pharmaceuticals | 4.06M | 1.44M | 1.8M | 1.79M | 2.57M | |||||
Total Assets | 53.06M | 43.09M | 35.27M | 17.93M | 15.23M | |||||
Interest Expense | -848K | -2.19M | -138K | -313K | -281K | |||||
Income Tax Expense | 100K | 285K | 17K | 377K | 261K | |||||
CAPEX | -139K | -488K | -183K | -319K | -1.32M | |||||
EBT | -5.84M | -19.28M | -20.33M | -23.55M | -4.64M | |||||
D&A | 598K | 530K | 477K | 12.98M | 4.43M | |||||
Operating Income | -5.14M | -16.73M | -20.29M | -23.72M | -4.34M | |||||
Net Income | -5.94M | -19.56M | -20.34M | -23.93M | -4.9M |
Geographical Revenue Distribution History
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Rest of The World | 4.06M | 1.44M | 1.8M | 1.79M | 1.87M | |||||
France | - | - | - | - | 701K | |||||
Total Assets | - | 22.51M | 22.28M | 13.36M | 10.46M | |||||
Other Europe | - | - | - | - | - | |||||
Europe | - | - | - | - | - |
- Stock Market
- Stocks
- ALVIO Stock
- C4X Stock
- Financials Valerio Therapeutics
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
